Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 3353 - 3360 of 12089 results
Mintz Levin Started Its Fiscal 2020 Mid-Pandemic, and Saw Profits Grow by a Third
March 18, 2021| News
BREAKING DOWN THE SPAC SURGE: A Review of Key Trends & Issues Defining the Phenomenon
March 18, 2021| Blog| Viewpoint
Health Law Diagnosed — Final Rules Amending the Anti-Kickback Statute and Stark Law Regulations: Part 2
March 17, 2021| Podcast| Viewpoint
Monthly TCPA Digest — March 2021
March 16, 2021| Article| Viewpoint
TCPA Legislative Update — Bipartisan Senate Bill Would Increase Fines for Spoofing
March 16, 2021| Article| Viewpoint
TCPA Regulatory Update — Industry Calls on FCC to Fix TCPA Consent Rule
March 16, 2021| Article| Viewpoint
ALERT: New COVID-19 Vaccine Paid Leave for New York Employees
March 16, 2021| Blog| Viewpoint
As Cleveland Searches for a Name, a Fan Roots for His Trademark
March 15, 2021| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|